1260PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma. (23rd October 2018) - Saiag, P; Robert, C; Grob, J J; Mortier, L; Dereure, O; Lebbe, C; Mansard, S; Grange, F; Neidhardt, E-M; Lesimple, T; Machet, L; Bedane, C; et al.